The global biological sk in substitutes market size was valued at USD 298.0 Billion in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.8% from 2023 to 2032.
Report Scope of the Biological Skin Substitutes Market:
|Market Size in 2022||USD 298.0 Billion|
|Revenue Forecast by 2032||USD 759.00 Billion|
|Growth rate from 2023 to 2032||9.8%|
|Report coverage||Type, Application, End-use|
|Regional scope||North America; Europe; Asia Pacific; Latin America; Middle East and Africa (MEA)|
|Key companies profiled||Organogenesis; Inc.; 3M; Integra LifeSciences; Smith and Nephew; Tissue Regenix; Mimedx; BSN medical; Stryker; Vericel Corporation.; Mallinckrodt (Stratatech Corporation)|
The Increasing prevalence of chronic wounds and the rising number of burn & trauma cases are expected to drive the market growth. Additionally, increasing demand for affordable skin-replacement solutions and the growing adoption of wound care facilities globally is expected further to propel the development of the market. Biological skin substitutes are tissue-engineered products specially designed to provide either permanent or temporary coverage to exposed skin wounds and help restore the affected part's skin functions. These products are widely used to treat chronic, non-healing ulcers (such as diabetic neuropathic ulcers, pressure ulcers, and vascular insufficiency ulcers). The skin substitutes can be differentiated into three main categories: epidermal replacement, dermal replacement, and dermal/epidermal replacement. They are also used as either temporary or permanent wound coverings.
Chronic wounds put a considerable and often neglected burden on patients, healthcare facilities, and society. It represents a silent epidemic that affects a significant portion of the global population. Furthermore, it is anticipated that around 2% of the population may suffer from a chronic wound during their lifetime in developed nations.
Several factors contribute to the upsurge in chronic wounds, including the aging population, the steep rise in the prevalence of obesity that is heavily correlated to diabetes, late effects of radiation therapies. According to a research article published by Mary Ann Liebert, Inc., in March 2021, around 2% of the U.S. population was affected by chronic wounds. In addition, 3% of the population over 65 years suffer from open wounds. Moreover, the U.S. government estimates that, by 2060, the elderly population will continue to rise above 77 Million, indicating that chronic wounds such as pressure ulcers, diabetic foot ulcers, etc., will continue to be an increasingly common problem among the elderly population by then.
The increase in number of reported burns, infections, skin diseases, trauma, etc., has increased the global demand for biological skin substitute products. These products aid in speedy healing and quick recovery of wounds. In addition, several campaigns have been launched by national governments across the globe to educate people about the advantages and importance of biologics for wound care has further propelled the biological skin substitutes market growth. The key players in the industry are providing advanced and better quality affordable biologics to increase their accessibility.
Furthermore, various medical institutions and research facilities are collaborating to develop modern approaches to wound management and trying to modernize wound care practices. For instance, In May 2022, MiMedx Group, Inc., a company that provides transformational placental biologics, announced that it had received a USD 4.6 Million award to evaluate a processed Dehydrated Human Amnion Chorion Membrane (DHACM) named PURION as an advanced solution for burn and wound care.
The WHO has been developing measures to reduce burn injuries and enhance burn care treatment globally in collaboration with The International Society for Burn Injuries (ISBI) and other related institutions. Tissue-engineered biological skin substitutes are classified under Class III medical devices. To assure the quality and safety of every medical product, the U.S. Food and Drug Administration (FDA) maintains the pre-market clearance process for scientific review of all Class III devices.
The COVID-19 pandemic had a negative impact on the biological skin substitutes market due to the decreased demand for these products and the disruption of supply chains and manufacturing processes. The market went down during the COVID-19 outbreak primarily due to the postponement or cancellation of elective surgeries, including those involving skin grafts and biological skin substitutes. This was done to preserve healthcare resources for the treatment of COVID-19 patients and to minimize the risk of infection among patients and healthcare workers.
Elective surgeries that involve biological skin substitutes, such as skin grafts or skin substitutes made from human or animal cells, are often non-urgent and can be delayed without significant harm to the patient. In 2021, approximately 10 Million of the population in the UK were waiting for surgical treatments, up from 4 Million before the pandemic. Furthermore, per the article published by the JAMA Network, in the U.S., over 13 Million surgical procedures from the 1st of January 2019 to the 30th of January 2021, there was a 48.0% decline in an overall surgical procedure following March 2020 recommendation to postpone elective surgeries.
Biological Skin Substitutes Market Segmentation:
Human Donor Tissue-Derived Products
Acellular Animal-derived Products
Research and Manufacturing